Moderna pushes for COVID-19 vaccine boosters in older adults, high-risk individuals

This post was originally published on this site

The company said its data supports the public health benefit of a booster dose of its vaccine to restore immune response, while reducing the number of “breakthrough” infections in fully-vaccinated adults.

Moderna (NASDAQ:MRNA)’s comments were released in briefing documents ahead of a Thursday and Friday meeting of the FDA’s outside expert advisers to discuss booster doses of Moderna and Johnson & Johnson (NYSE:JNJ)’s COVID-19 vaccines.

Rival Johnson & Johnson on Tuesday also cited data showing increased protection after a booster dose, which it said could be either administered as early as two months after the original dose of its vaccine.

Add Comment